691 related articles for article (PubMed ID: 18413790)
21. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
22. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
[TBL] [Abstract][Full Text] [Related]
23. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
24. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C
Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
[TBL] [Abstract][Full Text] [Related]
26. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
27. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
28. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
30. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Gray J; Cubitt CL; Zhang S; Chiappori A
Cancer Biol Ther; 2012 Jun; 13(8):614-22. PubMed ID: 22441819
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1.
Kumar P; Tripathi S; Pandey KN
J Biol Chem; 2014 Mar; 289(10):6991-7002. PubMed ID: 24451378
[TBL] [Abstract][Full Text] [Related]
32. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
Boumber Y; Younes A; Garcia-Manero G
Expert Opin Investig Drugs; 2011 Jun; 20(6):823-9. PubMed ID: 21554162
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
34. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
35. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
36. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
37. Antidepressant actions of histone deacetylase inhibitors.
Covington HE; Maze I; LaPlant QC; Vialou VF; Ohnishi YN; Berton O; Fass DM; Renthal W; Rush AJ; Wu EY; Ghose S; Krishnan V; Russo SJ; Tamminga C; Haggarty SJ; Nestler EJ
J Neurosci; 2009 Sep; 29(37):11451-60. PubMed ID: 19759294
[TBL] [Abstract][Full Text] [Related]
38. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Garcia-Manero G; Assouline S; Cortes J; Estrov Z; Kantarjian H; Yang H; Newsome WM; Miller WH; Rousseau C; Kalita A; Bonfils C; Dubay M; Patterson TA; Li Z; Besterman JM; Reid G; Laille E; Martell RE; Minden M
Blood; 2008 Aug; 112(4):981-9. PubMed ID: 18495956
[TBL] [Abstract][Full Text] [Related]
40. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
